Ask VialBase
healing · recovery

BPC-157

Also known as: Body Protection Compound 157, PL 14736, Bepecin, PL-10
FDA: Not FDA-approved WADA: Prohibited

BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid pentadecapeptide derived from a partial sequence of human gastric juice protein BPC. Unlike most peptides, BPC-157 is remarkably stable in gastric acid, allowing oral bioavailability — a property that underscores its origin as a gastric protective factor. With 213 PubMed publications as of April 2026, it is one of the most extensively studied research peptides for tissue repair, though nearly all evidence remains preclinical (animal and in-vitro studies). It has become a cornerstone compound in the peptide therapy community for healing protocols, often called "Wolverine peptide" for its broad regenerative effects

This content is for educational and research purposes only. VialBase does not provide medical advice. Consult a healthcare professional before using any peptide.

Molecular weight 1,419.53 Da
Half-life ~4 hours stable
CAS number —
Route Subcutaneous · Intramuscular · Oral · Topical subcutaneous preferred
02

Mechanism

Upregulates growth hormone receptors, modulates nitric oxide system (NO/NOS), promotes angiogenesis, activates FAK-paxillin pathway, modulates dopaminergic and serotonergic systems

03

Dosing

DOSE RANGE 250–500 mcg
FREQUENCY 1-2x daily
CYCLE LENGTH 4-12 weeks

Inject subcutaneously near injury site when targeting local repair. For systemic or gut healing, abdominal subcutaneous injection or oral administration. Often stacked with TB-500 for synergistic healing.

04

Research summary

Study Type Year Key Finding
Pentadecapeptide BPC 157 (PL 14736) Improves Ligament Healing in the Rat Animal study (rat model, controlled) 2010 BPC-157 significantly accelerated medial collateral ligament healing in rats
BPC 157 and Nitric Oxide System Comprehensive review 2018 BPC-157 modulates the nitric oxide (NO) system in a context-dependent manner
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance Narrative review 2026 BPC-157 demonstrates favorable tissue repair outcomes in animal models
Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications review 2016 BPC-157 modulates dopaminergic and serotonergic systems
Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts in-vitro 2014 BPC-157 increases growth hormone receptor expression in tendon fibroblasts
Stable gastric pentadecapeptide BPC 157-NO-system relation review 2014 BPC-157 interacts with the nitric oxide system as a key mechanism of action
Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full length article review 2013 BPC-157 promotes tendon-to-bone healing and tendon healing
Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat animal study 2010 BPC-157 significantly improved medial collateral ligament healing in rats
BPC-157 for Acute Hamstring Strain Repair — — —
05

Stacking & interactions

Enhanced systemic tissue repair — BPC-157 for local repair + TB-500 for systemic tissue remodeling and immune modulation

Wound healing + anti-aging synergy — collagen synthesis and tissue remodeling

Gut protection during GLP-1 therapy — mitigate GI side effects

Gut protection during GLP-1/GIP therapy

Stacks containing BPC-157

Marquee

Glow Stack

GHK-Cu + BPC-157 + TB-500

 Marquee

Wolverine Stack

BPC-157 + TB-500

Anti-Anxiety Reset

Selank + BPC-157 + DSIP

Athletic Recovery

BPC-157 + TB-500 + CJC/Ipamorelin

Estrogen Reset

BPC-157 + GHK-Cu + Arimistane

Recovery & Repair

BPC-157 + TB-500 + GHK-Cu

Spartan

CJC-1295 + Ipamorelin + IGF-1 LR3 + BPC-157

Tendon Armor

BPC-157 + TB-500 + Pentadecapeptide

TRT Off-Ramp

Kisspeptin-10 + Gonadotropin + BPC-157

28-day resets featuring BPC-157

06

Sourcing

Current prices

Updated today

5mg

10mg

20mg

Only vendor stocking this size on the VialBase roster.

500mg

Only vendor stocking this size on the VialBase roster.

Size unspecified

Stocks this compound Third-party tested Public COAs Positive rep

Save 20% with code VIALBASE at checkout

Stocks this compound Third-party tested Public COAs Positive rep
Stocks this compound Third-party tested Public COAs Positive rep

Save 15% with code VIALBASE at checkout

VialBase may earn a commission on purchases through partner links — never at additional cost to you. Full disclosure.

Also vetted at
What bloodwork do I need?

Reference ranges are general guidelines. Consult your physician for interpretation.

PRE-CYCLE
  • CMP
  • CBC
DURING CYCLE
  • CMP (if GI symptoms present)
POST-CYCLE
  • CMP
  • CBC
Safety & Regulatory Status
FDA STATUS Not FDA-approved. Category 2 per FDA's 503A bulk drug substance framework (demonstrably difficult to compound). Previously Category 1 as of Feb 2026 reclassification — verify current status.
WADA STATUS Prohibited (S0 category — non-approved substances, effective January 2022)

Regulatory status for BPC-157 may change. Verify current status with your jurisdiction before use. This is not legal or medical advice.

References

  1. Cerovecki T, Bojanic I, Brcic L, et al.. Pentadecapeptide BPC 157 (PL 14736) Improves Ligament Healing in the Rat. Journal of Orthopaedic Research (2010). PMID: 21030672
  2. Sikiric P, Rucman R, Turkovic B, et al.. BPC 157 and Nitric Oxide System. Current Pharmaceutical Design (2018). PMID: 30915550
  3. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Medicine (2026). PMID: 41966639
  4. Sikiric, P., Seiwerth, S., Rucman, R. et al.. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Current Neuropharmacology (2016). PMID: 26813123
  5. Chang, C.H., Tsai, W.C., Lin, M.S. et al.. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules (2014). PMID: 25587787
  6. Sikiric, P., Seiwerth, S., Rucman, R. et al.. Stable gastric pentadecapeptide BPC 157-NO-system relation. Current Pharmaceutical Design (2014). PMID: 24001295
  7. Sikiric, P., Seiwerth, S., Rucman, R. et al.. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full length article. Current Pharmaceutical Design (2013). PMID: 23782143
  8. Cerovecki, T., Bojanic, I., Brcic, L. et al.. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. Journal of Orthopaedic Research (2010). PMID: 20135673
  9. BPC-157 for Acute Hamstring Strain Repair.